Free Trial
→ SpaceX will mint billionaires. You won't be one of them. (From Behind the Markets) (Ad)tc pixel
NASDAQ:THAR

Tharimmune Q2 2024 Earnings Report

Tharimmune logo
$3.09 +0.07 (+2.32%)
As of 06/12/2026
ProfileEarnings HistoryForecast

Tharimmune EPS Results

Actual EPS
-$2.42
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Tharimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tharimmune Announcement Details

Quarter
Q2 2024
Date
8/9/2024
Time
N/A
Conference Call Date
Friday, August 9, 2024
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Tharimmune's Q2 2024 Quarterly reportQuarterly report
(10-Q)

Tharimmune Earnings Headlines

Tharimmune (NASDAQ:THAR) Trading Up 15.2% - Still a Buy?
June 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30829974
Tharimmune Inc.
May 13, 2026  |  wsj.comhttps://www.wsj.com/market-data/quotes/MX/XMEX/THAR
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel
June 15 at 1:00 AM  |  Weiss Ratings (Ad)
Tharimmune Rebrands as Canton Strategic Holdings, Updates Ticker
February 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tharimmune-rebrands-as-canton-strategic-holdings-updates-ticker?utm_source=marketbeat.com&utm_medium=referral
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
February 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tharimmune-inc-announces-corporate-rebrand-to-canton-strategic-holdings-inc-marking-milestone-in-canton-network-digital-asset-treasury-strategy-302689437.html
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact
February 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/catherine-woods-strategic-moves-closer-230121661.html
See More Tharimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tharimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tharimmune and other key companies, straight to your email.

About Tharimmune

Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

View Tharimmune Profile
Earnings Tools